Paul G. Richardson Boeken

Richardson and Anderson, both teachers of medicine at Harvard Medical School, compile novel therapies being developed to target specific molecular pathways involved in the oncogenesis of myeloma. Chapters cover epidemiology and molecular pathogenesis, mechanisms of drug resistance, thalidomide treatment, bone disease, high-dose chemotherapy, supportive care, and novel biological therapies. The book will be of interest to specialist hematologists and oncologists and other healthcare providers. Annotation ©2004 Book News, Inc., Portland, OR (booknews.com)